Model Estimates Herd Immunity Threshold for COVID-19
A mathematical model shows that SARS-CoV-2 disease-induced herd immunity level may be lower than the classical model assuming homogenous immunization.
Vaccines
Reactogenicity of Enhanced Influenza Vaccines in Older Adults
A team of investigators report on the findings from a randomized controlled trial of 3 enhanced influenza vaccines and a standard-dose vaccine in older adults.
First Large Clinical Trial of COVID-19 Vaccine Could Begin in July
A large clinical trial of the first US COVID-19 vaccine could begin next month, according to Moderna Inc., which developed the vaccine with the US National Institutes of Health.
HPV Vaccine Toolkit Increases Vaccination Rates in Primary Care
The purpose of this project is to implement and evaluate the effectiveness of the 4 Pillars Practice Transformation Program to increase uptake of the HPV vaccine among pediatric patients.
School-Based Health Centers Help Minimize Pediatric Under-Immunization
School-based health centers minimized the number of students excluded from school from under-immunization.
Adenovirus Type-5 Vectored COVID-19 Vaccine Shows Promise
A recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine is safe, tolerable, and immunogenic.
Moderna’s COVID-19 Vaccine Gets Fast Track Designation
The FDA has granted Fast Track designation to the vaccine candidate, mRNA-1273 (Moderna), against the novel coronavirus (SARS-CoV-2).
AAP: Declines in Immunization During COVID-19 Pandemic Concerning
The AAP has issued a statement regarding recent data published by the Centers for Disease Control and Prevention (CDC) about a decline in pediatric vaccination during the COVID-19 pandemic.
Influenza Vaccine Not Linked to Decrease in Hospitalizations or Mortality Among Elderly
Targeting the elderly (individuals aged 65 years) for influenza vaccination may not decrease hospitalization or mortality rates in this population.
FDA Approves Quadrivalent Meningococcal Vaccine MenQuadfi
The FDA has approved MenQuadfiTM Meningococcal (Groups A, C, Y, W; Sanofi Pasteur) Conjugate Vaccine for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in patients aged ≥2 years.
-
Loading...
-
Loading...
Next post in Vaccine Information Center
